Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/35851
Title: Tolerogenic dendritic cells attenuate experimental autoimmune antimyeloperoxidase glomerulonephritis.
Authors: Ito K.;Richard Kitching A.;Gan P.-Y.;Odobasic D.;Oudin V.;Holdsworth S.R. 
Institution: (Odobasic, Oudin, Ito, Gan, Richard Kitching, Holdsworth) Centre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Australia (Ito) Division of Nephrology and Rheumatology, Fukuoka University School of Medicine, Fukuoka, Japan (Richard Kitching) Department of Pediatric Nephrology, Monash Health, Clayton, Australia (Richard Kitching, Holdsworth) Department of Nephrology, Monash Health, Clayton, Australia (Holdsworth) Department of Immunology, Monash Health, Clayton, Australia
Issue Date: 15-Nov-2019
Copyright year: 2019
Publisher: American Society of Nephrology (E-mail: email@asn-online.org)
Place of publication: United States
Publication information: Journal of the American Society of Nephrology. 30 (11) (pp 2140-2157), 2019. Date of Publication: 2019.
Journal: Journal of the American Society of Nephrology
Abstract: Background Because of their capacity to induce antigen-specific immunosuppression, tolerogenic dendritic cells are a promising tool for treatment of autoimmune conditions, such as GN caused by autoimmunity against myeloperoxidase (MPO). Methods We sought to generate tolerogenic dendritic cells to suppress anti-MPO GN by culturing bone marrow cells with an NFkB inhibitor (BAY 11-7082) and exposing them to a pulse of MPO. After administering these MPO/BAY dendritic cells or saline to mice with established anti-MPO or anti-methylated BSA (mBSA) immunity, we assessed immune responses and GN. We also examined mechanisms of action of MPO/BAY dendritic cells. Results MPO/BAY dendritic cells decreased anti-MPO immunity and GN without inhibiting immune responses against mBSA; they also induced IL-10-producing regulatory T cells in MPO-immunized mice without affecting IL-10+ CD4+Foxp32 type 1 regulatory T cells or regulatory B cells. MPO/BAY dendritic cells did not inhibit anti-MPO immunity when CD4+Foxp3+ cells were depleted in vivo, showing that regulatory T cells are required for their effects. Coculture experiments with dendritic cells and CD4+Foxp32 or CD4+Foxp3+ cells showed that MPO/BAY dendritic cells generate Foxp3+ regulatory T cells from CD4+Foxp32 cells through several pathways, and induce IL-10+ regulatory T cells via inducible costimulator (ICOS), which was confirmed in vivo. Transfer of MPO/BAY dendritic cell-induced regulatory T cells in vivo, with or without anti-IL-10 receptor antibody, demonstrated that they suppress anti-MPO immunity and GN via IL-10. Conclusions MPO/BAY dendritic cells attenuate established anti-MPO autoimmunity and GN in an antigen-specific manner through ICOS-dependent induction of IL-10-expressing regulatory T cells. This suggests that autoantigen-loaded tolerogenic dendritic cells may represent a novel antigen-specific therapeutic option for anti-MPO GN.Copyright © 2019 by the American Society of Nephrology.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1681/ASN.2019030236
PubMed URL: 31444274 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31444274]
ISSN: 1046-6673
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/35851
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

36
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.